The FDA gave Antisense a rare pediatric disease designation last month, which makes the treatment eligible for a regulatory voucher that could be traded on secondary markets for hundreds of millions of dollars.Antisense says that ATL1102 could have a “profound” impact on boys with DMD, in slowing the muscle wasting associated with the disease. A phase 2b study is planned for next year..
Ann: Percheron to present at 2024 BIO International Convention, page-17
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
